Home
About BCG
Contact Us
Locations
Services
Areas of Expertise
Regulatory Library
Newsletter Archive
Useful Web Links
Presentations
 


 

 

 

 

 

 

 

 

 

 

SUMMARY OF EXPERTISE

  • Extensive experience in new drug/biologic registration, regulatory compliance and quality assurance.
  • Strong management and leadership abilities.
  • Experienced in establishing and developing regulatory affairs and quality assurance systems.
  • In-depth knowledge of FDA regulations for GMP's, GCP's and GLP's.

EDUCATION:

M.S.   Quality Assurance & Regulatory Affairs, Temple University, Graduate School of Pharmacy, Ambler, PA.
M.B.A.   Seton Hall University, Graduate School of Business, South Orange, NJ.
B.S.   Biology, Brooklyn College, Brooklyn, NY.


EXPERIENCE:
CURRENT POSITION
(Dec. 2006 - present)
  Senior Consultant Biologics Consulting Group Inc.
Belle Mead, NJ
   
2006  

Vice President, Worldwide Regulatory Affairs, Ethicon, Inc.
Somerville, NJ

  • Led and directed worldwide regulatory affairs functions for new product registrations (devices and device combination products) and post-approval regulatory activities.
  • Responsible for identifying and analyzing changes in worldwide regulatory requirements and developing strategies to address those changes relevant to the company's products.
  • Responsible for regulatory review and approval of advertising/promotional materials and labeling.
   
2001 - 2005  

Vice President, Regulatory Policy & Quality Assurance, Covance, Inc.,
Princeton, NJ

  • Responsible for all regulatory, quality assurance and compliance activities associated with Phase II-IV clinical research.
  • Directed multifunctional regulatory projects for client companies including preparing, and submitting clinical trial and marketing approval applications and developing strategies for drug approval.
  • Launched strategic regulatory consulting unit to assist small pharmaceuticals and biotech companies in developing and gaining approval of novel drugs and biologics.
  • Developed a regulatory policy unit to assess and address changes to regulatory requirements for the development and approval of drugs and biologics.
  • Globalized clinical quality assurance organization; harmonized processes and procedures to address worldwide clinical research requirements.
 
1999 - 2000  

Vice President, Regulatory Affairs & Quality Assurance, ImClone Systems, Inc.
Somerville, NJ

  • Developed regulatory strategies and directed regulatory and quality activities to gain FDA approval of therapeutic monoclonal antibodies and vaccines.
  • Expanded and upgraded the quality assurance, validations and regulatory affairs departments to support multiple product development and pre-commercialization programs.
  • Directed the regulatory activities for several important FDA meetings clearing the path for successful BLA filings.
  • Established the framework for FDA to grant Fast Track Designation for the company's lead product. Secured Orphan Drug Designation for the same product.
 
1996 - 1999  

Vice President, Regulatory Affairs & Quality Assurance, Cytogen Corp.
Princeton, NJ

  • Developed and directed regulatory and quality assurance activities to secure approval of prescription drugs and biologics (Phases I-IV).
  • Established advertising /labeling policies and quality assurance systems.
  • Developed a corporate quality policy for regulatory, clinical and manufacturing activities
  • Developed quality systems and procedures for the manufacture of multiple biologic products.
 
1993 - 1996  

Senior Director, Regulatory Affairs, Pharmacia, Inc.
Columbus, OH

  • Developed and implemented regulatory strategies for the approval of prescription drug products within the U.S.
  • Successfully coordinated NDA submission activities of drug products for cancer, urology, rheumatoid arthritis, ulcerative colitis and smoking cessation.
  • Centralized the regulatory affairs organization enabling the standardization of practices and procedures resulting in higher quality NDA submissions and faster drug approvals.
  • Key regulatory affairs representative in merger transition team between Pharmacia and Upjohn
 
1981 - 1993  

Executive Director, Regulatory Affairs, Pharmacia Laboratories (Kabi Pharmacia, Inc.), Piscataway, NJ

  • Directed US regulatory activities including new drug registration and compliance with FDA regulations and guidelines.
  • Directed and coordinated the successful filing of several NDAs and NDA supplements.
  • Spearheaded the company's US taskforce for expediting the global approval of new drugs.
  • Led FDA negotiations and directed the regulatory activities to address compliance issues facing the company.
  • Developed and implemented a reorganization plan to centralize the regulatory affairs department.
  • Liaison to FDA during plant inspections. Conducted internal GMP, GLP and GCP audits
 
1977 - 1981  

U.S. Food and Drug Administration, East Orange, NJ

  • Performed establishment inspections of drugs, medical devices and in-vitro diagnostics.
  • Experienced with FDA regulations including GMP's, GCP's and GLP's.
  • Received four letters of commendation for superior performance.

CERTIFICATIONS AND RELATED ACTIVITIES
  • Regulatory Affairs Certified (RAC)
  • Chair, Ethics & Clinical Practice Committee, Association of Clinical Research Organizations
  • Chair, Ethics Committee, Regulatory Affairs Professional Society
  • Editorial Board, FOCUS, Regulatory Affairs Professional Society
  • Instructor, Regulatory and Legal Issues in Drug Development, Mercer County Community College

Page Updated January 3, 2007




 


See BCG announcement